documents
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
93 rows where docket_id = "FDA-2009-N-0582" sorted by posted_date descending
This data as json, CSV (advanced)
Suggested facets: subtype, posted_date, posted_month, posted_date (date), comment_start_date (date), comment_end_date (date), last_modified (date)
document_type 5
- Supporting & Related Material 86
- Proposed Rule 3
- Rule 2
- Notice 1
- Other 1
agency_id 1
- FDA 93
| id | agency_id | docket_id | title | document_type | subtype | posted_date ▲ | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-2009-N-0582-0132 | FDA | None FDA-2009-N-0582 | TAB A-2016-994-Direct to Consumer-Final Rule-Original | Supporting & Related Material | Background Material | 2024-01-05T05:00:00Z | 2024 | 1 | 2024-01-05T13:40:49Z | 0 | 0 | 0900006486375b66 | |||
| FDA-2009-N-0582-0131 | FDA | None FDA-2009-N-0582 | Direct to Consumer Memorandum | Supporting & Related Material | Memorandum | 2024-01-05T05:00:00Z | 2024 | 1 | 2024-01-05T13:40:49Z | 0 | 0 | 0900006486375b65 | |||
| FDA-2009-N-0582-0135 | FDA | None FDA-2009-N-0582 | TAB B-2016-994-Direct to Consumer-FRIA-TRACK CHANGE FROM ORIGINAL TO FINAL | Supporting & Related Material | Background Material | 2024-01-05T05:00:00Z | 2024 | 1 | 2024-01-05T13:40:51Z | 0 | 0 | 0900006486375b69 | |||
| FDA-2009-N-0582-0134 | FDA | None FDA-2009-N-0582 | TAB B-2016-994-Direct to Consumer-Final Rule-TRACK CHANGE FROM ORIGINAL TO FINAL | Supporting & Related Material | Background Material | 2024-01-05T05:00:00Z | 2024 | 1 | 2024-01-05T13:40:50Z | 0 | 0 | 0900006486375b68 | |||
| FDA-2009-N-0582-0136 | FDA | None FDA-2009-N-0582 | TAB C-2016-994-Direct to Consumer FRIA-Final | Supporting & Related Material | Background Material | 2024-01-05T05:00:00Z | 2024 | 1 | 2024-01-05T13:40:52Z | 0 | 0 | 0900006486375b6a | |||
| FDA-2009-N-0582-0133 | FDA | None FDA-2009-N-0582 | TAB-A-2016-994-Direct to Consumer-FRIA-Orginal | Supporting & Related Material | Background Material | 2024-01-05T05:00:00Z | 2024 | 1 | 2024-01-05T13:40:50Z | 0 | 0 | 0900006486375b67 | |||
| FDA-2009-N-0582-0137 | FDA | None FDA-2009-N-0582 | TAB C-2016-994-Direct to Consumer-Final Rule-Final | Supporting & Related Material | Background Material | 2024-01-05T05:00:00Z | 2024 | 1 | 2024-01-05T13:40:52Z | 0 | 0 | 0900006486375b6b | |||
| FDA-2009-N-0582-0130 | FDA | None FDA-2009-N-0582 | Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format Final Rule: Questions and Answers; Guidance for Industry; Small Entity Compliance Guide; Availability | Rule | Final Rule with Request for Comments | 2023-12-27T05:00:00Z | 2023 | 12 | 2023-12-27T05:00:00Z | 2023-12-27T14:34:36Z | 2023-28530 | 0 | 0 | 090000648635c371 | |
| FDA-2009-N-0582-0129 | FDA | None FDA-2009-N-0582 | Agency Information Collection Activities; Proposals, Submissions, and Approvals | Notice | Notice of Approval | 2023-12-22T05:00:00Z | 2023 | 12 | 2024-01-08T13:23:07Z | 2023-28290 | 0 | 0 | 0900006486351614 | ||
| FDA-2009-N-0582-0061 | FDA | None FDA-2009-N-0582 | Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Rule | Direct Final Rule | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T05:00:00Z | 2024-01-05T14:03:16Z | 2023-25428 | 0 | 0 | 090000648629f6eb | |
| FDA-2009-N-0582-0070 | FDA | None FDA-2009-N-0582 | 08 Reference 8 How DTC Spending Shifted in 2020_Medical Marketing and Media_2021 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:16:07Z | 0 | 0 | 090000648629f8c1 | |||
| FDA-2009-N-0582-0090 | FDA | None FDA-2009-N-0582 | 28 Reference 28 Capacity Limits in Selective Attention Behavioral Evidence and Implications for Neural Activity_Lavie_2001 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:31:22Z | 0 | 0 | 09000064862a052d | |||
| FDA-2009-N-0582-0092 | FDA | None FDA-2009-N-0582 | 30 Reference 30 Temporal Methods for Studying Attention How Did We Get Here and Where Are We Going_Shapiro_2001 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:32:32Z | 0 | 0 | 09000064862a052f | |||
| FDA-2009-N-0582-0115 | FDA | None FDA-2009-N-0582 | 53 Reference 53 The Implications of the FTC's Clear and Conspicuous Standards for the Communication of Credit Card Information to Young Consumers_Thomas_2011 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:42:50Z | 0 | 0 | 09000064862a0679 | |||
| FDA-2009-N-0582-0105 | FDA | None FDA-2009-N-0582 | 43 Reference 43 Aging and Direct-to-Consumer Prescription Drug Television Ads The Effects of Individual Differences and Risk Presentation_O'Donoghue_2019 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:40:54Z | 0 | 0 | 09000064862a058f | |||
| FDA-2009-N-0582-0112 | FDA | None FDA-2009-N-0582 | 50 Reference 50 H. Rept. No.102-839_1992 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:42:11Z | 0 | 0 | 09000064862a05d8 | |||
| FDA-2009-N-0582-0103 | FDA | None FDA-2009-N-0582 | 41 Reference 41 Age Affective Experience and Television Use_Depp_2010 | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:40:41Z | 0 | 0 | 09000064862a05da | |||
| FDA-2009-N-0582-0118 | FDA | None FDA-2009-N-0582 | 56 Reference 56 Effect of Presentation Modality in Direct-to-Consumer (DTC) Prescription Drug Television Advertisements_Wogalter_2014 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:43:24Z | 0 | 0 | 09000064862a06c3 | |||
| FDA-2009-N-0582-0062 | FDA | None FDA-2009-N-0582 | 00 References List CCN Final Rule 10-24-23 | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:11:41Z | 0 | 0 | 090000648629f897 | |||
| FDA-2009-N-0582-0064 | FDA | None FDA-2009-N-0582 | 02 Reference 2 Direct-to-Consumer Advertising of Prescription Drugs and the Patient Prescriber Encounter A Systematic Review_DeFrank_2020 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:12:03Z | 0 | 0 | 090000648629f899 | |||
| FDA-2009-N-0582-0076 | FDA | None FDA-2009-N-0582 | 14 Reference 14 Factors Influencing Consumers' Attitudinal and Behavioral Responses to Direct-to-Consumer and Over-the-Counter Drug Advertising_Lee_2015 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:17:49Z | 0 | 0 | 090000648629f8c7 | |||
| FDA-2009-N-0582-0086 | FDA | None FDA-2009-N-0582 | 24 Reference 24 An Integrated Career Coaching and Time-Banking System Promoting FlexibilityWellness and Success A Pilot Program at Stanford University School of Medicine_Fassiotto_2018 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:20:34Z | 0 | 0 | 09000064862a0528 | |||
| FDA-2009-N-0582-0088 | FDA | None FDA-2009-N-0582 | 26 Reference 26 Draft Guidance for Industry Presenting Risk Information in Prescription Drug and Medical Device Promotion_FDA_2009 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:20:50Z | 0 | 0 | 09000064862a052a | |||
| FDA-2009-N-0582-0097 | FDA | None FDA-2009-N-0582 | 35 Reference 35 Music is as Distracting as Noise The Differential Distraction of Background Music and Noise on the Cognitive Test Performance of Introverts and Extraverts_Furnham_2002 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:39:39Z | 0 | 0 | 09000064862a058b | |||
| FDA-2009-N-0582-0100 | FDA | None FDA-2009-N-0582 | 38 Reference 38 Sources of Miscomprehension in Television Advertising_Hoyer_1984 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:39:57Z | 0 | 0 | 09000064862a058e | |||
| FDA-2009-N-0582-0108 | FDA | None FDA-2009-N-0582 | 46 Reference 46 Provision of Effective Information_Baker_2006 | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:41:44Z | 0 | 0 | 09000064862a05dc | |||
| FDA-2009-N-0582-0091 | FDA | None FDA-2009-N-0582 | 29 Reference 29 The Magical Number Seven Plus or Minus Two Some Limits on Our Capacity for Processing Information_Miller_1956 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:32:20Z | 0 | 0 | 09000064862a052e | |||
| FDA-2009-N-0582-0099 | FDA | None FDA-2009-N-0582 | 37 Reference 37 Distraction and Attitude Change A Resolution_Regan_1973 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:39:51Z | 0 | 0 | 09000064862a058d | |||
| FDA-2009-N-0582-0110 | FDA | None FDA-2009-N-0582 | 48 Reference 48 Quantifying Perceived Differences in Type Styles An Exploratory Study_Tantillo_1995 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:41:58Z | 0 | 0 | 09000064862a0591 | |||
| FDA-2009-N-0582-0079 | FDA | None FDA-2009-N-0582 | 17 Reference 17 Consumers Reports on the Health Effects of Direct-to-Consumer Drug AdvertisingWeissman2003 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:18:38Z | 0 | 0 | 090000648629f8f6 | |||
| FDA-2009-N-0582-0083 | FDA | None FDA-2009-N-0582 | 21 Reference 21 Time Allocation in Primary Care Office Visits_Tai-Seale_2007 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:19:39Z | 0 | 0 | 090000648629f8fa | |||
| FDA-2009-N-0582-0116 | FDA | None FDA-2009-N-0582 | 54 Reference 54 An Empirical Examination of the FDAAA-Mandated Toll-Free Statement for Consumer Reporting of Side Effects in Direct-to-Consumer Television Advertisements_Aikin_2016 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:43:00Z | 0 | 0 | 09000064862a06ad | |||
| FDA-2009-N-0582-0109 | FDA | None FDA-2009-N-0582 | 47 Reference 47 Text Legibility and the Letter Superiority Effect_Sheedy_2005 | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:41:50Z | 0 | 0 | 09000064862a05de | |||
| FDA-2009-N-0582-0125 | FDA | None FDA-2009-N-0582 | 63 Reference 63 Defining Audio-Video Redundancy From a Limited-Capacity Information Processing Perspective_Lang_1995 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:44:22Z | 0 | 0 | 09000064862a067a | |||
| FDA-2009-N-0582-0120 | FDA | None FDA-2009-N-0582 | 58 Reference 58 The Empirical Case for Dual Coding_Paivio_1983 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:43:43Z | 0 | 0 | 09000064862a067b | |||
| FDA-2009-N-0582-0074 | FDA | None FDA-2009-N-0582 | 12 Reference 12 Kaiser Health Tracking Poll October 2015_DiJulio_2015 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:17:32Z | 0 | 0 | 090000648629f8c5 | |||
| FDA-2009-N-0582-0080 | FDA | None FDA-2009-N-0582 | 18 Reference 18 Fair Balance in Direct-to-Consumer Antidepressant Print and Television Advertising_Avery_2012 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:18:51Z | 0 | 0 | 090000648629f8f7 | |||
| FDA-2009-N-0582-0089 | FDA | None FDA-2009-N-0582 | 27 Reference 27 Experimental Evaluation of the Impact of Distraction on Consumer Understanding of Risk and Benefit Information Technical Research Report_FDA_2011RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:21:06Z | 0 | 0 | 09000064862a052b | |||
| FDA-2009-N-0582-0075 | FDA | None FDA-2009-N-0582 | 13 Reference 13 2017 Direct-to-Consumer Advertising Survey Results_Princeton Survey Research Associates for PhRMA_2017 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:17:38Z | 0 | 0 | 090000648629f8c6 | |||
| FDA-2009-N-0582-0065 | FDA | None FDA-2009-N-0582 | 03 Reference 3 Promotion of Prescription Drugs to Consumers and Providers 20012010_Kornfield_2013 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:12:12Z | 0 | 0 | 09000064862a084c | |||
| FDA-2009-N-0582-0093 | FDA | None FDA-2009-N-0582 | 31 Reference 31 Factors That Guide or Disrupt Attentive Visual Processing_Hillstrom_2006 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:32:38Z | 0 | 0 | 09000064862a0530 | |||
| FDA-2009-N-0582-0101 | FDA | None FDA-2009-N-0582 | 39 Reference 39 The Effect of Background Music and Background Noise on the Task Performance of Introverts and Extraverts_Cassidy_2007 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:40:21Z | 0 | 0 | 09000064862a0590 | |||
| FDA-2009-N-0582-0106 | FDA | None FDA-2009-N-0582 | 44 Reference 44 Quantifying and Predicting the Effects of Basic Text Display Variables on the Perceived Urgency of Warning Labels_Adams_1995 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:41:18Z | 0 | 0 | 09000064862a05d5 | |||
| FDA-2009-N-0582-0113 | FDA | None FDA-2009-N-0582 | 51 Reference 51 The Self-Confidence Advertising Response Relationship A Function of Situational Disctraction_Bither_1973 | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:42:23Z | 0 | 0 | 09000064862a0614 | |||
| FDA-2009-N-0582-0127 | FDA | None FDA-2009-N-0582 | 65 Reference 65 Commission Enforcement Policy Statement in Regard to Clear and Conspicuous Disclosure in Television Advertising_FTC_1970 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:44:39Z | 0 | 0 | 09000064862a067f | |||
| FDA-2009-N-0582-0096 | FDA | None FDA-2009-N-0582 | 34 Reference 34 Comprehension of Info-Aid Supers in Television Advertising for Social Ideas Implications for Public Policy_Manrai_1994 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:32:58Z | 0 | 0 | 09000064862a058a | |||
| FDA-2009-N-0582-0123 | FDA | None FDA-2009-N-0582 | 61 Reference 61 What Effect Do Mixed Sensory Mode Instructional Formats Have on Both Novice and Experienced Learners of Chinese Characters_Chung_2008 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:44:03Z | 0 | 0 | 09000064862a06c5 | |||
| FDA-2009-N-0582-0082 | FDA | None FDA-2009-N-0582 | 20 Reference 20 Patients Willing to Wait Arrival Time Wait Time and Patient Satisfaction in an Ambulatory Urology Clinic_Donahue_2017 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:19:10Z | 0 | 0 | 090000648629f8f9 | |||
| FDA-2009-N-0582-0084 | FDA | None FDA-2009-N-0582 | 22 Reference 22 A Time Motion Study of Primary Care Physicians' Work in the Electronic Health Record Era_Young_2018 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:20:14Z | 0 | 0 | 090000648629f8fb | |||
| FDA-2009-N-0582-0063 | FDA | None FDA-2009-N-0582 | 01 Reference 1 Guidance for Industry Consumer-Directed Broadcast Advertisements_FDA_1999 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:11:52Z | 0 | 0 | 090000648629f898 | |||
| FDA-2009-N-0582-0066 | FDA | None FDA-2009-N-0582 | 04 Reference 4 Trends in Exposure to Televised Prescription Drug Advertising 20032011Kornfield2015 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:15:07Z | 0 | 0 | 090000648629f89a | |||
| FDA-2009-N-0582-0121 | FDA | None FDA-2009-N-0582 | 59 Reference 59 The Effects of Audio-Visual and Visual-Only Cues on Consumers Responses to Co-Branded Advertising_Wang_2010 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:43:49Z | 0 | 0 | 09000064862a06ae | |||
| FDA-2009-N-0582-0072 | FDA | None FDA-2009-N-0582 | 10 Reference 10 An Updated Analysis of DTC TV Advertisements for Prescription Drugs_Applequist_2018 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:16:58Z | 0 | 0 | 090000648629f8c3 | |||
| FDA-2009-N-0582-0077 | FDA | None FDA-2009-N-0582 | 15 Reference 15 Patient and Physician Attitudes and Behaviors Associated With DTC Promotion of Prescription Drugs Summary of FDA Survey Research Results_Aikin_2004 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:17:59Z | 0 | 0 | 090000648629f8f4 | |||
| FDA-2009-N-0582-0111 | FDA | None FDA-2009-N-0582 | 49 Reference 49 Effects of Label Format on Knowledge Acquisition and Perceived Readability by Younger and Older Adults_Wogalter_2003 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:42:05Z | 0 | 0 | 09000064862a05d6 | |||
| FDA-2009-N-0582-0128 | FDA | None FDA-2009-N-0582 | 66 Reference 66 Economic Analysis of Impacts Direct-to-Consumer Prescription Drug Advertisements_FDA_2023 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:44:49Z | 0 | 0 | 09000064862a06b2 | |||
| FDA-2009-N-0582-0104 | FDA | None FDA-2009-N-0582 | 42 Reference 42 Prescription Drug Use Continues to Increase U.S. Prescription Drug Data for 20072008 NCHS Data Brief_Gu_2010 | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:40:47Z | 0 | 0 | 09000064862a05dd | |||
| FDA-2009-N-0582-0119 | FDA | None FDA-2009-N-0582 | 57 Reference 57 Cognitive Psychology In and Out of the Laboratory_Galotti_2004 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:43:38Z | 0 | 0 | 09000064862a0676 | |||
| FDA-2009-N-0582-0117 | FDA | None FDA-2009-N-0582 | 55 Reference 55 Attention to and Distraction from Risk Information in Prescription Drug Advertising An Eye Tracking Study_Sullivan_2017 | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:43:07Z | 0 | 0 | 09000064862a06c0 | |||
| FDA-2009-N-0582-0094 | FDA | None FDA-2009-N-0582 | 32 Reference 32 Distraction Can Enhance or Reduce Yielding to Propaganda Thought Disruption Versus Effort Justification_Petty_1976 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:32:43Z | 0 | 0 | 09000064862a0588 | |||
| FDA-2009-N-0582-0095 | FDA | None FDA-2009-N-0582 | 33 Reference 33 Modifying the Impact of Persuasive Communications with External Distraction_Zimbardo_1970 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:32:48Z | 0 | 0 | 09000064862a0589 | |||
| FDA-2009-N-0582-0102 | FDA | None FDA-2009-N-0582 | 40 Reference 40 Clear and Conspicuous Disclosure_CCH Trade Regulation Reporter_1970 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:40:31Z | 0 | 0 | 09000064862a05d7 | |||
| FDA-2009-N-0582-0107 | FDA | None FDA-2009-N-0582 | 45 Reference 45 Serifs and Font Legibility_Arditi_2005 | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:41:35Z | 0 | 0 | 09000064862a05d9 | |||
| FDA-2009-N-0582-0126 | FDA | None FDA-2009-N-0582 | 64 Reference 64 Recall of Television Versus Print News Retesting the Semantic Overlap Hypothesis_Walma_2004 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:44:32Z | 0 | 0 | 09000064862a067c | |||
| FDA-2009-N-0582-0068 | FDA | None FDA-2009-N-0582 | 06 Reference 6 Trends in Urological Direct-to-Consumer Advertising during Prime-Time Television News Programs_Koo_2017 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:15:23Z | 0 | 0 | 090000648629f8bf | |||
| FDA-2009-N-0582-0073 | FDA | None FDA-2009-N-0582 | 11 Reference 11 PhRMA Guiding Principles Direct to Consumer Advertisements About Prescription Medicines_PhRMA_2008 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:17:18Z | 0 | 0 | 090000648629f8c4 | |||
| FDA-2009-N-0582-0069 | FDA | None FDA-2009-N-0582 | 07 Reference 7 US Congressional Research Service_Direct-to-Consumer Advertising of Prescription Drugs Report_2009 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:15:34Z | 0 | 0 | 090000648629f8c0 | |||
| FDA-2009-N-0582-0078 | FDA | None FDA-2009-N-0582 | 16 Reference 16 Scientific Literature on Direct-to-Consumer Advertising of Prescription Pharmaceuticals 20042008 Literature ReviewEastern Research Group2009 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:18:08Z | 0 | 0 | 090000648629f8f5 | |||
| FDA-2009-N-0582-0071 | FDA | None FDA-2009-N-0582 | 09 Reference 9 The Top 10 Ad Spenders in Big Pharma for 2020_Fierce Pharma_Bulik 2021 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:16:16Z | 0 | 0 | 090000648629f8c2 | |||
| FDA-2009-N-0582-0081 | FDA | None FDA-2009-N-0582 | 19 Reference 19 Communicating Uncertainties About Prescription Drugs to the Public A National Randomized Trial_Schwartz_2011 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:18:59Z | 0 | 0 | 090000648629f8f8 | |||
| FDA-2009-N-0582-0085 | FDA | None FDA-2009-N-0582 | 23 Reference 23 Direct-to-Consumer Advertising Physicians' Views of Its Effects on Quality of Care and the Doctor-Patient Relationship_Murray_2003 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:20:26Z | 0 | 0 | 09000064862a0527 | |||
| FDA-2009-N-0582-0087 | FDA | None FDA-2009-N-0582 | 25 Reference 25 Allocation of Physician Time in Ambulatory Practice A Time and Motion Study in 4 Specialties_Sinsky_2016 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:20:43Z | 0 | 0 | 09000064862a0529 | |||
| FDA-2009-N-0582-0124 | FDA | None FDA-2009-N-0582 | 62 Reference 62 Using Both an Auditory and a Visual Short-Term Store to Increase Digit Span_Frick_1984 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:44:17Z | 0 | 0 | 09000064862a061d | |||
| FDA-2009-N-0582-0114 | FDA | None FDA-2009-N-0582 | 52 Reference 52 Music to Your Brain Background Music Changes Are Processed First Reducing Ad Message Recall_Fraser_2013 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:42:40Z | 0 | 0 | 09000064862a061b | |||
| FDA-2009-N-0582-0098 | FDA | None FDA-2009-N-0582 | 36 Reference 36 Processing Deficits and the Mediation of Positive Affect in Persuasion_Mackie_1989 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:39:46Z | 0 | 0 | 09000064862a058c | |||
| FDA-2009-N-0582-0122 | FDA | None FDA-2009-N-0582 | 60 Reference 60 Improving Comprehension of Jury Instructions with Audio-Visual Presentation_Brewer_2004 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:43:59Z | 0 | 0 | 09000064862a06c2 | |||
| FDA-2009-N-0582-0067 | FDA | None FDA-2009-N-0582 | 05 Reference 5 Do Prescription Drug Ads Tell Consumers Enough About Benefits and Side Effects Results From the Health Information National Trends Survey Fourth_Sullivan_2015 RE:Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format | Supporting & Related Material | Background Material | 2023-11-21T05:00:00Z | 2023 | 11 | 2023-11-21T22:15:15Z | 0 | 0 | 090000648629f89b | |||
| FDA-2009-N-0582-0055 | FDA | None FDA-2009-N-0582 | Direct-to-Consumer Prescription Drug Advertisements; Presentation of the Major Statement in Television and Radio Advertisements in a Clear, Conspicuous, and Neutral Manner; Reopening of the Comment Period | Proposed Rule | Notice of Proposed Rulemaking (NPRM) | 2012-03-23T04:00:00Z | 2012 | 3 | 2012-03-23T04:00:00Z | 2012-04-10T03:59:59Z | 2023-10-25T16:01:08Z | 2012-06948 | 0 | 0 | 0900006480fdf3d2 |
| FDA-2009-N-0582-0040 | FDA | None FDA-2009-N-0582 | Direct-to-Consumer Prescription Drug Advertisements; Presentation of the Major Statement in Television and Radio Advertisements in a Clear, Conspicuous, and Neutral Manner; Notice of Availability of Study Data | Proposed Rule | Notice of Proposed Rulemaking (NPRM) | 2012-01-27T05:00:00Z | 2012 | 1 | 2012-01-27T05:00:00Z | 2012-02-28T04:59:59Z | 2023-10-25T16:02:27Z | 2012-01672 | 0 | 0 | 0900006480fa7047 |
| FDA-2009-N-0582-0017 | FDA | None FDA-2009-N-0582 | OMB Changes, Executive Order 12866 (E.O.)[Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in Television and Radio Advertisements in a Clear, Conspicuous, and Neutral Manner ] - Reference | Other | REF-Reference Material (internal attachments) | 2010-04-27T04:00:00Z | 2010 | 4 | 2010-04-27T04:00:00Z | 2013-08-11T01:34:04Z | 0 | 0 | 0900006480ae15c4 | ||
| FDA-2009-N-0582-0007 | FDA | None FDA-2009-N-0582 | Reference 12 - "IMS Health, Total U.S. Promotional Spend By Type, 2008" - Background | Supporting & Related Material | BKG-Background Material | 2010-03-29T04:00:00Z | 2010 | 3 | 2010-03-29T15:20:19Z | 0 | 0 | 0900006480ac9fd4 | |||
| FDA-2009-N-0582-0008 | FDA | None FDA-2009-N-0582 | Reference 13 - "IMS Health, Integrated Promotional Services™, Year 2008, Data Extracted on September 2009" - Background | Supporting & Related Material | BKG-Background Material | 2010-03-29T04:00:00Z | 2010 | 3 | 2010-03-29T15:20:40Z | 0 | 0 | 0900006480ac9fd9 | |||
| FDA-2009-N-0582-0009 | FDA | None FDA-2009-N-0582 | Reference 15 - "Office of Management and Budget, Circular A-4, Setember 17, 2003" - Background | Supporting & Related Material | BKG-Background Material | 2010-03-29T04:00:00Z | 2010 | 3 | 2010-03-29T15:21:01Z | 0 | 0 | 0900006480ac9ffb | |||
| FDA-2009-N-0582-0013 | FDA | None FDA-2009-N-0582 | Reference 19 - "Scientific Literature on Direct to Consumer Advertising of Precription Pharmaceuticals, 2004-2008; Eastern Research Group, Inc., Literature Review" - Background | Supporting & Related Material | BKG-Background Material | 2010-03-29T04:00:00Z | 2010 | 3 | 2010-03-29T15:22:43Z | 0 | 0 | 0900006480aca060 | |||
| FDA-2009-N-0582-0003 | FDA | None FDA-2009-N-0582 | Reference 1 - "FDA Guidance for Industry, "Consumer-Directed Broadcast Advertisements," - Background | Supporting & Related Material | BKG-Background Material | 2010-03-29T04:00:00Z | 2010 | 3 | 2010-03-29T15:18:52Z | 0 | 0 | 0900006480ac9f70 | |||
| FDA-2009-N-0582-0002 | FDA | None FDA-2009-N-0582 | DDMAC References - [Note for MONDAY 3/29/2010 - POST THIS DOCUMENT FIRST BUT AFTER THE FR DOCUMENT AND Please Insert the Title of the FR Notice Here] | Supporting & Related Material | BKG-Background Material | 2010-03-29T04:00:00Z | 2010 | 3 | 2010-03-29T15:18:23Z | 0 | 0 | 0900006480aca149 | |||
| FDA-2009-N-0582-0001 | FDA | None FDA-2009-N-0582 | Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in Television and Radio Advertisements in a Clear, Conspicuous, and Neutral Manner | Proposed Rule | NPR-Notice of Proposed Rule-Making | 2010-03-29T04:00:00Z | 2010 | 3 | 2010-03-29T04:00:00Z | 2010-06-29T03:59:59Z | 2012-11-30T03:02:04Z | 2010-06996 | 0 | 0 | 0900006480aca825 |
| FDA-2009-N-0582-0010 | FDA | None FDA-2009-N-0582 | Reference 16 - "Prescription Drugs: FDA Oversight of Direct-to-Consumer Advertising Has Limitations, GAO" - Background | Supporting & Related Material | BKG-Background Material | 2010-03-29T04:00:00Z | 2010 | 3 | 2010-03-29T15:21:25Z | 0 | 0 | 0900006480aca03c | |||
| FDA-2009-N-0582-0006 | FDA | None FDA-2009-N-0582 | Reference 4 - "FDA Draft Guidance for Industry, "Presenting Risk Information in Prescription Drug and Medical Device Promotion," - Background | Supporting & Related Material | BKG-Background Material | 2010-03-29T04:00:00Z | 2010 | 3 | 2010-03-29T15:19:59Z | 0 | 0 | 0900006480ac9f89 | |||
| FDA-2009-N-0582-0004 | FDA | None FDA-2009-N-0582 | Reference 2 - "CCH Trade Regulation Reporter, Paragraph 7569.09 "Clear and Conspicous Disclosure," Ocober 21, 1970 - Background | Supporting & Related Material | BKG-Background Material | 2010-03-29T04:00:00Z | 2010 | 3 | 2010-03-29T15:19:13Z | 0 | 0 | 0900006480ac9f86 | |||
| FDA-2009-N-0582-0011 | FDA | None FDA-2009-N-0582 | Reference 17 - "PhRMA Guiding Priniciples; Direct to Consumer Advertisements About Prescription Medicines, Revised December 2008" - Background | Supporting & Related Material | BKG-Background Material | 2010-03-29T04:00:00Z | 2010 | 3 | 2010-03-29T15:21:45Z | 0 | 0 | 0900006480aca040 | |||
| FDA-2009-N-0582-0012 | FDA | None FDA-2009-N-0582 | Reference 18 - "Patient and Physician Attitudes and Behaviors Associated With DTC Promotion of Prescription Drugs--Summary of FDA Survey Research Results, Final Report, November 19, 2004" - Background | Supporting & Related Material | BKG-Background Material | 2010-03-29T04:00:00Z | 2010 | 3 | 2010-03-29T15:22:06Z | 0 | 0 | 0900006480aca044 | |||
| FDA-2009-N-0582-0005 | FDA | None FDA-2009-N-0582 | Reference 3 - "See H. Rept. No. 102-839, August 11, 1992" - Background | Supporting & Related Material | BKG-Background Material | 2010-03-29T04:00:00Z | 2010 | 3 | 2010-03-29T15:19:36Z | 0 | 0 | 0900006480ac9f87 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE documents (
id TEXT PRIMARY KEY,
agency_id TEXT,
docket_id TEXT REFERENCES dockets(id),
title TEXT,
document_type TEXT,
subtype TEXT,
posted_date TEXT,
posted_year INTEGER,
posted_month INTEGER,
comment_start_date TEXT,
comment_end_date TEXT,
last_modified TEXT,
fr_doc_num TEXT,
open_for_comment INTEGER,
withdrawn INTEGER,
object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date) WHERE comment_end_date IS NOT NULL AND withdrawn = 0;